Synthetic biology-based vaccin developer Delonix Bioworks has completed a round co-led by Boehringer Ingelheim Venture Fund.

Boehringer Ingelheim has co-led a $14m series A round for China-based vaccine developer Delonix Bioworks through corporate venturing unit Boehringer Ingelheim Venture Fund (BIVF).

The round was co-led with venture capital group IDG Capital and also featured VC firm ZhenFund and an undisclosed additional investor.

Delonix is developing vaccines using synthetic biology and gene editing, and its lead product candidate is targeted at anti-microbial resistance (AMR).

Weiyi Zhang, managing director of BIVF China, said: “The Delonix team has developed a…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn